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OBJECTIVES: Polycystic Ovary Syndrome (PCOS) is one of the
most common endocrine disorders affecting ﬁve to ten percent of
young women. Aside from its cutaneous symptoms and repro-
ductive morbidity, PCOS associates with metabolic syndrome
and an increased risk of cardiovascular events. In recent years the
use of Metformin, an insulin sensitizer, in PCOS has aroused a
great interest. Metformin administration restores ovulatory men-
strual cycles and seems to improve infertility. However, the extent
to which this agent improves the metabolic and cardiovascular
risk factors associated with PCOS remains uncertain. Our aim
was to assess the effectiveness of Metformin in improving clinical
and metabolic features of PCOS. METHODS: Systematic
Review (up to February 2008) and meta-analysis of randomized
controlled trials that compared Metformin versus placebo or
other standard therapies for PCOS such as oral contraceptive
pills (OCPs) and measured metabolic and cardiovascular param-
eters. Studies were critically appraised. Pooled estimates of effect
were based on a random-effects model. Odds Ratio and
Weighted Mean Difference, with 95% conﬁdence interval, used
were appropriate. Consistency across studies was evaluated by
means of the I-square statistic. Potential reasons for heterogene-
ity were explored. RESULTS: Of 120 candidate studies, 19 trials
were eligible. Methodological quality of these trials was low.
Meta-analyses showed a small decrease in BMI and systolic
blood pressure in women treated with Metformin compared to
placebo. The other parameters including waist circumference,
waist-hip ratio, diastolic blood pressure, fasting blood glucose,
insulin levels and lipid proﬁle did not differ between the groups.
As against OCPs, Metformin signiﬁcantly reduced the BMI but
no other signiﬁcant differences were observed. CONCLUSIONS:
Scant and inconsistent evidence suggest that Metformin provide
limited or no important beneﬁt for metabolic derangements and
cardiovascular risk factors in women with PCOS. Further
research is needed to solve this important health issue.
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OBJECTIVES: To evaluate the effectivity of an education
program, measuring the percentage of patients with blood pres-
sure control at the end of a follow-up period in comparison to
baseline. METHODS: Prospective and multicentric study real-
ized in Hypertension Units (HU) and Primary Care (PC) centers
in Spain. Physicians included outpatients 18 years with not
controlled essential hypertension (BP > 140/90 or BP > 130/
80 mmHg if diabetic or previous CV events and BP < 180/
110 mmHg). Patients were followed for ﬁve months in four
scheduled visits. At V0 blood pressure, patient demographics,
medical and drug history, CV risk factors and lifestyle were
assessed using standardized methods. Between V0 and V1 the
intervention consists in medical education for physicians on CV
risk control and guidelines. During V1 and V2 patients received
education and support. At V3 we assessed the overall interven-
tion in BP control. Informed consent was obtained. RESULTS: A
total of 316 patients were recruited, 64.2% in PC and 35.8% in
HU centers (62.8  12.1 years, 51.6% males, BMI 29.8 
5.1 Kg/m2). Mean ofﬁce BP was 156.0  14.3/89.4  10.9
(mean AMPB daytime 141.4  12.7/86.5  11.3) mmHg at
baseline. Obesity (60.6%), dyslipemia (53.4%), type-2 diabetes
(23.1%), target organ damage (16.6%), smoking habits (16.6%)
and coronary artery disease (12.8%) were the most prevalent CV
risk factors. A total of 82.4% of patients completed satisfactorily
the intervention. Mean BP had a decreasing trend along the
study: at V1 mean BP was 143.1  16.9/82.8  11.5, at V2 was
137  13.1/79,5  9.1 and at V3 was 135.0  12.4/77,8  8.8.
At the end of the study 52.7% of patients reach the BP goal
during the 5–month intervention study. CONCLUSIONS: Based
on this results, medical and patient education determine a greater
BP control, hence more educational actions are needed to
increase BP control.
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OBJECTIVES: PAAF is becoming an increasingly common thera-
peutic procedure for symptomatic AF. Until recently, oral anti-
coagulation regimens remained in place even after a successful
ablative procedure. Recent clinical debate, however, suggests that
oral anticoagulation could be discontinued after an ablation,
should the patient be free from AF. ICMs can be used immedi-
ately after the ablation procedure to verify freedom from asymp-
tomatic AF recurrence. If the patient remains free from
symptomatic and asymptomatic AF recurrences, OAC may be
discontinued. The ICM will also alert the patient of any recur-
rences after OAC has been stopped. In this way, OAC can be
restarted if needed. We sought to examine the cost-effectiveness
of this OAC management strategy. METHODS: We developed a
Markov Decision Analytic Model in TreeAge Pro Version 8 for
Health care. Literature searches were performed for risk of AF
recurrence; risk of stroke; risk of OAC adverse effects; and, risks
of anti-arrhythmic adverse effects. Utilities for the various health
states were also found in the literature. Costs were based of the
UK NHS. RESULTS: Using ICM to manage oral anticoagulation
proved cost-effective within the three-year lifespan of the device.
The ICER was estimated at £27,582 per QALY gained. CON-
CLUSIONS: Managing oral anticoagulation in this patient popu-
lation is a newly developed concept. This strategy has the
potential to allow individuals restricted in their daily activities by
OAC treatment to resume their normal lives. Our analysis has
shown that OAC management can be cost-effective. Further
work is needed to assess the cost-effectiveness implications over
a longer timeframe and to identify the patient subgroups where
the economic beneﬁts of OAC management are maximized.
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OBJECTIVES: This paper aims at discussing hospital managers’
consideration of costs vs. tariffs (i.e. DRGs) when decisions on
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